Roche reported a 3% decline in diagnostic division revenues for H1 2025, weighed down by healthcare pricing reforms and volume-based procurement programs in China, leading to a 26% drop in local sales. Despite this, excluding China, diagnostics revenues rose 6%, supporting a 4% overall sales increase and strong net income growth. The company is managing cost structures amidst these headwinds and maintains guidance for mid-single-digit constant currency growth. Continued investment in advanced products and focus on other international markets underpin Roche's resilience.